FORA Capital LLC Buys New Holdings in Moderna, Inc. (NASDAQ:MRNA)

FORA Capital LLC acquired a new position in Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 73,728 shares of the company's stock, valued at approximately $3,066,000.

Several other institutional investors have also recently bought and sold shares of the stock. Wilmington Savings Fund Society FSB raised its position in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after acquiring an additional 587 shares during the last quarter. Compass Planning Associates Inc bought a new stake in shares of Moderna during the 4th quarter valued at $37,000. Venturi Wealth Management LLC raised its position in shares of Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after acquiring an additional 664 shares during the last quarter. Crowley Wealth Management Inc. bought a new stake in shares of Moderna during the 4th quarter valued at $41,000. Finally, Itau Unibanco Holding S.A. raised its position in shares of Moderna by 51.2% during the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after acquiring an additional 343 shares during the last quarter. Institutional investors own 75.33% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently commented on MRNA shares. Barclays lowered their price objective on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a research report on Friday, May 2nd. The Goldman Sachs Group cut shares of Moderna from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $99.00 to $51.00 in a research report on Wednesday, January 29th. UBS Group lowered their price objective on shares of Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Morgan Stanley lowered their price objective on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research report on Wednesday, April 9th. Finally, Leerink Partners lowered their price objective on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a research report on Thursday, January 16th. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Moderna currently has an average rating of "Hold" and an average target price of $53.95.

Moderna Trading Down 0.5%

Shares of Moderna stock traded down $0.13 during trading hours on Friday, reaching $24.25. 7,118,541 shares of the company's stock were exchanged, compared to its average volume of 7,591,726. The company has a 50 day moving average of $28.89 and a two-hundred day moving average of $36.34. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $170.47. The stock has a market cap of $9.38 billion, a P/E ratio of -2.61 and a beta of 1.99.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, topping analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The company had revenue of $108.00 million during the quarter, compared to the consensus estimate of $130.35 million. During the same period in the prior year, the business posted ($3.07) EPS. The company's quarterly revenue was down 35.3% on a year-over-year basis. As a group, analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.